




A Comprehensive Whole Genome Sequencing Test for Blood Cancers

ULTRASENSITIVE BLOOD OR BONE MARROW TEST FOR DEEP GENETIC INSIGHTS TO GUIDE PERSONALIZED THERAPY SELECTION.

DETECTING RESISTANCE TO IMMUNOTHERAPIES



GenoPredicta enables detection of genetic therapy resistance mechanisms, including deletions or mutations of immunotherapy targets.

In a clinical sample from a patient with prior BCMA- and GPRC5D-targeting therapies, alterations leading to loss of both targets were observed by WGS: biallelic deletion of GPRC5D, deletion coupled with a loss-of-function mutation in BCMA.

Clinically validated in myeloma and being developed for other blood cancers—*GenoPredicta is flow cytometry-based detection and enumeration, cytogenetics, NGS, all in one test.*

COMPREHENSIVE GENOMIC INSIGHTS

Comprehensive characterization of genetic alterations in tumor cells — copy number changes, translocations, and point mutations, including in therapy target genes.

MINIMAL INPUT, BETTER SENSITIVITY

Currently validated for as few as 50 circulating tumor cells (CTCs) — equivalent to a sensitivity of 10^{-6} — and aiming for lower in follow-on assays, GenoPredicta delivers comprehensive WGS at a fraction of the input required by competing assays. This exceptional sensitivity at the MRD level expands testing eligibility to patients with low tumor burden, limited sample volumes, or challenging collection conditions where other assays fall short.


100% CONCORDANCE OF BLOOD AND BONE MARROW

GenoPredicta on CTCs captures the same information as GenoPredicta on bone marrow, and can more comprehensively characterize disease — e.g., in cases with extramedullary and disseminated disease.


GENOPREDICTA CAN REPLACE BONE MARROW BIOPSY

GenoPredicta™ on bone marrow and peripheral blood shows **100% concordance**

Bone Marrow



Peripheral Blood



While the initial diagnosis of multiple myeloma still requires a bone marrow biopsy, future follow-up monitoring may not. Current tests like FISH require painful biopsies to collect malignant plasma cells, making ongoing monitoring difficult. GenoPredicta addresses this issue by collecting as few as ~50 circulating tumor cells from peripheral blood, allowing for better prognostication without the need for a invasive biopsies.



ADVANTAGES OF WGS-BASED PROFILING OF CTCs


	FISH	NGS Panels	GenoPredicta (WGS)	
	Marrow only*	Marrow only*	Marrow	Blood (CTCs)
Sample type	Marrow only*	Marrow only*	Marrow	Blood (CTCs)
Minimally invasive	X	X	X	✓
Cell requirements	50-200/probe	Generally > 1,600 (10ng DNA)	~50	~50
Genetic alterations: SVs (translocations) CNVs Focal CNVs SNVs/indels Copy-neutral LOH	Only canonical Limited x x x	Only canonical/covered Limited Only if covered Only if covered Limited	✓ ✓ ✓ ✓ ✓	✓ ✓ ✓ ✓ ✓
Satisfies NCCN guidelines	X	✓	✓	✓
Detects mutations / deletions of therapeutic targets	X	Only if covered	✓	✓
Discovers new resistance markers	X	Only in covered	✓	✓
Robust detection of subclonal alterations	X	X	✓	✓
Representative of all lesions/ clones, not just sampled site	X	X	X	✓

GenoPredicta is a cutting-edge, WGS-based test for the comprehensive characterization of blood cancer genomes, from as few as 50 CTCs. The table shows a head-to-head comparison of GenoPredicta with other tests.

*Assumption of high % of tumor cells in sample (e.g., CD138-selected cells)

GENOPREDICTA CAN REPLACE BONE MARROW BIOPSY

- GenoPredicta enables accurate detection of subclonal events
- Subclonal characterization can elucidate tumor evolutionary history and thus predict evolution in response to treatment
- GenoPredicta from CTCs enables detecting alterations from multiple lesions, including EMD



➔ BLOOD CAN CAPTURE SIGNAL FROM MULTIPLE LESIONS AND PROVIDE MORE COMPLETE INFORMATION ABOUT THE TUMOR